DDInter1628 DDInter342
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK3
PLK3 {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Ruxolitinib {u} (Compound) binds {v} (Gene) BMP2K
BMP2K {u} (Gene) is bound by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Ruxolitinib {u} (Compound) binds {v} (Gene) LRRK2
LRRK2 {u} (Gene) is bound by {v} (Compound) Bosutinib
Bosutinib {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Ruxolitinib {u} (Compound) binds {v} (Gene) IRAK1
IRAK1 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is palliated by {v} (Compound) Methylprednisolone
Methylprednisolone {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Ruxolitinib {u} (Compound) binds {v} (Gene) PHKG2
PHKG2 {u} (Gene) is upregulated by {v} (Compound) Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Ruxolitinib {u} (Compound) upregulates {v} (Gene) FOXJ3
FOXJ3 {u} (Gene) is upregulated by {v} (Compound) Azacitidine
Azacitidine {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Ruxolitinib {u} (Compound) upregulates {v} (Gene) WAPAL
WAPAL {u} (Gene) is downregulated by {v} (Compound) Topotecan
Topotecan {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib (Compound) and Nilotinib may lead to a major life threatening interaction when taken with Certolizumab pegol
Ruxolitinib (Compound) binds PLK3 (Gene) and PLK3 (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may lead to a major life threatening interaction when taken with Certolizumab pegol
Ruxolitinib (Compound) binds BMP2K (Gene) and BMP2K (Gene) is bound by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Ruxolitinib (Compound) binds LRRK2 (Gene) and LRRK2 (Gene) is bound by Bosutinib (Compound) and Bosutinib may lead to a major life threatening interaction when taken with Certolizumab pegol
Ruxolitinib (Compound) binds IRAK1 (Gene) and IRAK1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Certolizumab pegol
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is palliated by Methylprednisolone (Compound) and Methylprednisolone may lead to a major life threatening interaction when taken with Certolizumab pegol
Ruxolitinib (Compound) binds PLK1 (Gene) and PLK1 (Gene) is downregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Ruxolitinib (Compound) binds PHKG2 (Gene) and PHKG2 (Gene) is upregulated by Chloramphenicol (Compound) and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Ruxolitinib (Compound) upregulates FOXJ3 (Gene) and FOXJ3 (Gene) is upregulated by Azacitidine (Compound) and Azacitidine may lead to a major life threatening interaction when taken with Certolizumab pegol
Ruxolitinib (Compound) upregulates WAPAL (Gene) and WAPAL (Gene) is downregulated by Topotecan (Compound) and Topotecan may lead to a major life threatening interaction when taken with Certolizumab pegol